Through the agreement with UH Bristol, PAREXEL expands alliance network to support early phase patient studies.
UH Bristol, a provider of medical and dental teaching, is a research center and one of the acute NHS Trusts in the country.
PAREXEL early phase head and corporate vice president Sy Pretorius said UH Bristol has experience in clinical research, access to substantial patient populations, and work across multiple therapeutic areas.
UH Bristol research director David Wynick said they look forward to work with PAREXEL to expand their research portfolio for the benefit of patients.